Physician profile
Jonathan D Jones
NPI 1003868720
$759.01
in general payments reported to CMS, 2019-2025
13 companies · $376 in 2025
The $376 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.44 · 2023: $300 · 2024: $49.50 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $245.00 | 2025 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $121.61 | 2023 | |
| Alexion Pharmaceuticals, INC. | $93.35 | 2023 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $85.07 | 2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $75.19 | 2025 | Wegovy |
| Ucb, INC. | $38.44 | 2025 | Bimzelx |
| Abbvie INC. | $26.31 | 2024 | |
| Glaxosmithkline, LLC. | $23.19 | 2024 | Benlysta |
| Horizon Therapeutics Plc | $20.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.41 | 2025 | Enhertu |
| Pfizer INC. | $13.13 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.